Emerging roles for proteinases in cancer

Invasion and Metastasis

Volumn 17, Issue 5, 1997, Pages 221-239

  Noël, Agnès ^a   Gilles, C ^a   Bajou, K ^a   Devy, L ^a   Kebers, F ^a   Lewalle, J M ^a   Maquoi, E ^a   Munaut, C ^a   Remacle, A ^a   Foidart, J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cancer invasion; Proteinases; Tumor growth

Indexed keywords

CELL SURFACE PROTEIN; GROWTH FACTOR; MATRIX PROTEIN; METALLOPROTEINASE; PROTEINASE; SERINE PROTEINASE;

ANGIOGENESIS; APOPTOSIS; BIOAVAILABILITY; CANCER INVASION; CANCER THERAPY; CELL MIGRATION; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; MOUSE; NONHUMAN; REVIEW; TUMOR GROWTH;

ANIMALS; CELL MOVEMENT; ENDOPEPTIDASES; EXTRACELLULAR MATRIX; GELATINASES; GROWTH SUBSTANCES; HUMANS; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SERINE ENDOPEPTIDASES;

EID: 0037655672     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Twining SS: Regulation of proteolytic activity in tissues. Crit Rev Biochem Mol Biol 1994;29:315-383.
2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
3. Chapman HA, Riese RJ, Shi G-P: Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997;59:63-88.
4. Murphy G, Knäuper V: Relating matrix metalloproteinase structure to function: Why the 'hemopexin' domain? Matrix Biol 1997;15:511-518.
5. Kute TE, Grøndahl-Hansen J, Shao S-M, Long R, Russell G, Brünner N: Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998;47:9-16.
6. Chenard MP, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq JP, Duffy MJ: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer (Pred Oncol) 1996;69:448-451.
7. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-423.
8. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S: Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 1997;272:22389-22392.
9. Masson R, Lefèbvre O, Noël A, Chenard MP, Wendung C, Kebers F, Lemeur M, Dierich A, Foidart JM, Basset P, Rio MC: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;100:1535-1541.
10. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD: Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 1996;93:3942-3946.
11. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997;94:1402-1407.
12. Vu TH, Shipley MJ, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93:411-422.
13. DeClerck YA, Imren S, Montgomery AMP, Mueller BM, Reisfeld RA, Laug WE: Proteases and protease inhibitors in tumor progression; in Church et al. (eds): Chemistry and Biology of Serpins. New York, Plenum Press, 1997, pp 89-97.
14. Keppler D, Sameni M, Moin K, Mikkelsen T, Diglio CA, Sloane BF: Tumor progression and angiogenesis: Cathepsin B & Co. Biochem Cell Biol 1996;74:799-810.
15. Basset P, Okada O, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC: Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications. Matrix Biol 1997;15:535-541.
16. Rudolph-Owen LA, Matrisian LM: Matrix metalloproteinases in remodeling of the normal and neoplastic mammary gland. J Mam Gland Biol Neoplasia 1998;3:177-190.
17. Stöcker W, Bode W: Structural features of a superfamily of zinc-endopeptidases: The metzincins. Curr Opin Struct Biol 1995;5:383-390.
18. Seiki M: Membrane type-matrix metalloproteinase and tumor invasion. Curr Top Microbiol Immunol 1996;213:23-32.
19. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE: Multiple modes of activation of latent human fibroblast collagenase: Evidence for the role of a Cys73 active-size zinc complex in latency and a 'cysteine switch' mechanism for activation. Proc Natl Acad Sci USA 1990;87:364-368.
20. Edwards DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, Lim MS: The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth. Int J Obesity 1996;20:S9-S15.
21. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767-2774.
22. Conese M, Blasi F: Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol Chem Hoppe-Seyler 1995;376:143-155.
23. Gensberg K, Jan S, Matthews GM: Subtilisin-related serine proteases in the mammalian constitutive secretory pathway. Cell Dev Biol 1998;9: 11-17.
24. Seidah NG, Chrétien M, Day R: The family of subtilisin/kexin like pro-protein and pro-hormone convertases: Divergent or shared functions. Biochimie 1994;76:207-209.
25. Montgomery AMP, DeClerck YA, Langley KE, Reisfeld RA, Mueller BM: Melanoma-mediated dissolution of extracellular matrix: Contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 1993; 53:693-700.
26. Santavicca M, Noël A, Stoll I, Segain JP, Angliker H, Anglard P, Chrétien M, Seidah N, Bassel P: Characterisation of structural determinants and molecular mechanisms involved in stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Biochem J 1996;315:953-958.
27. Maquoi E, Noël A, Frankenne F, Angliker H, Murphy G, Foidart JM: Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett 1998;424:262-266.
28. Carmeliet P, Moons L, Lijnen R, Baes M, Eemaître V, Tipping P, Drew A, Eeckhout Y, Shapito S, Lupu F, Collen D: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439-444.
29. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noël A, Foidart JM: Involvement of PA/Plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997;405:157-162.
30. Devy L, Noël A, Baramova E, Bajou K, Trentesaux C, Jardillier JC, Foidart JM, Jeannesson P: Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells. Biochem Biophys Res Commun 1997;238: 842-846.
31. Zhang Z, Winyard PG, Chidwick K, Murphy G, Wardell M, Carrel RW, Blake DR: Proteolysis of human native and oxidised alpha 1-proteinase inhibitor by matrilysin and stromelysin. Biochim Biophys Acta 1994; 19:224-228.
32. 1-antitrypsin. Biochem Biophys Res Commun 1994;204:613-620.
33. Noël A, Santavicca M, Stoll I, L'Hoir C, Staub A, Murphy G, Rio MC, Basset P: Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities. J Biol Chem 1995;270:22866-22872.
34. Wolsberg TG, White JM: ADAMs in fertilization and development. Dev Biol 1996;180:389-401.
35. Wu E, Croucher PI, McKie N: Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 1997;235:437-442.
36. Blobel CP: Metalloprotease-disintegrins: Link to cell adhesion and cleavage of TNF alpha and Notch. Cell 1997;90:589-592.
37. Millichip MI, Dallas DJ, Wu E, Dale S, McKie N: The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 1998;245:594-598.
38. Rosendahl MS, Ko SC, Long DL, Brewer MT, Rosenzweig B, Hedl E, Anderson L, Pyle SM, Moreland J, Meyers MA, Kohno T, Lyons D, Lichtenstein HS: Identification and characterization of a pro-tumor necrosis factor-a-processing enzyme from the ADAM family zinc metalloproteases. J Biol Chem 1997;272: 24588-24593.
39. Liotta LA: Cancer cell invasion and metastasis. Sci Am 1992;266:34-41.
40. Opdenakker G, Van Damme J: Cytokines and proteases in invasive processes: Molecular similarities between inflammation and cancer. Cytokines 1992;4:35-40.
41. Nawrocki B, Polette M, Marchand V, Maquoi E, Beorchia A, Tournier JM, Foidart JM, Birembaut P: Membrane-type matrix metalloproteinase-1 expression at the site of human placentation. Placenta 1996; 17:565-572.
42. Maquoi E, Polette M, Nawrocki B, Bischof P, Noël A, Pintiaux A, Santavicca M, Schaaps JP, Pijnenborg P, Biremhaut P, Foidart JM: Expression of stromelysin-3 in the human placenta and plancental bed. Placenta 1997;18:277-285.
43. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284:67-68.
44. MacDougall JR, Matrisian LM: Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995;14: 351-362.
45. Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Cancer Biol 1996;7:147-154.
46. Coussens LM, Werb Z: Matrix metalloproteinases and development of cancer. Chem Biol 1996;3:895-904.
47. Yu AE, Hewitt RE, Kleiner DE, Stetler-Stevenson WG: Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2. Biochem Cell Biol 1996;74:823-831.
48. Polette M, Gilbert N, Stas I, Nawrocki B, Noël A, Remacle A, Stetler-Stevenson WG, Birembaut P, Foidart JM: Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Archiv 1994;424: 641-645.
49. Schnack-Nielsen B, Sehested M, Timshel S, Pyke C, Dano K: Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996;74:168-177.
50. Schnack-Nielsen B, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K: Expression of matrix metalloproteinase-9 in vascular pericytes in human breast cancer. Lab Invest 1997;77:345-355.
51. Noël A, Polette M, Lewalle JM, Munaut C, Emonard H, Birembaut P, Foidart JM: Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast adenocarcinoma cells. Int J Cancer 1994;56:331-336.
52. Ito A, Nakajima S, Sasaguri Y, Nagase H, Mori Y: Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer 1995;71: 1039-1045.
53. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
54. D'Armiento J, DiColandrea T, Dalal SS, Okada Y, Huang MT, Conney AH: Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 1995;15:5732-5739.
55. Sympson CJ, Bissel MJ, Werb Z: Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol 1995;6:159-163.
56. Witty JP, McDonnell S, Newell K, Canon P, Navre M, Tressler R, Matrisian LM: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994;54:4805-4812.
57. Noël A, Lefèbvre O, Maquoi E, Vanhoorde L, Chenard MP, Mareel M, Foidart JM, Basset P, Rio MC: Stromelysin-3 expression promote tumor taken in nude mice. J Clin Invest 1996;97:1924-1930.
58. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994;54:5467-5473.
59. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-708.
60. Imren S, Kohn DB, Shimada H, Blavier L, DeClerck YA: Overexpression of tissue inhibitor of metalloproteinases-2 by retroviral mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996;56:2891-2895.
61. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995;87:1546-1550.
62. Talbot DC, Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996;32A:2528-2533.
63. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75.
64. Noël A, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle JM, Remade A, Kebers F, Brown P, Calberg-Bacq CM, Foidart JM: Inhibition of stromal matrix metalloproteases: Effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998;76:267-273.
65. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996; 271:10079-10086.
66. Noël A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapière CM, Foidart JM: Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer 1993; 68:909-915.
67. Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990;346: 281-284.
68. Plouët J, Moro F, Bertagnolli S, Coldebœuf N, Mazarguil H, Clamens S, Bayard F: Extracellular cleavage of the vascular endothelial growth factor 189-amino form by urokinase is required for its mitogenic effect. J Biol Chem 1997;272:13390-13396.
69. Manes S, Mira E, del Mar Barbacid M, Cipres A, Fernandez-Resa P, Buesa JM, Mérida I, Aracil M, Marquez G, Martinez-A C: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997; 272:25706-25712.
70. Collett-Solberg PF, Cohen P: The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996;25:591-614.
71. Oh Y: IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 1998;47:283-293.
72. Roskelley CD, Srebrow A, Bissell MJ: A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol 1995;7:736-747.
73. Weaver VM, Fischer AH, Peterson OW, Bissell MJ: The importance of the microenvironment in breast cancer progression: Recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. Biochem Cell Biol 1997;74:833-851.
74. Boudreau N, Sympson CJ, Werb Z, Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995;267:891-893.
75. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-1164.
76. 3 rescues melanoma cells from apoptosis in a three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994;91: 8856-8860.
77. Sympson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissell MJ, Werb Z: Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol 1994;125:681-693.
78. Witty JP, Wright JH, Matrisian LM: Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development. Mol Biol Cell 1995;6:1287-1303.
79. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:231-245.
80. Hulboy DL, Rudolph LA, Matrisian LM: Matrix metalloproteinases as mediators of reproductive function. Hum Reprod 1997;3:27-45.
81. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
82. Hu G-F, Riordan JF, Vallee BL: Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA 1994;91:12096-12100.
83. Kakeji Y, Teicher BA: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15: 39-48.
84. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy A, Bird RE, Hoyhtya M, Fuerst TR, Quigley J, French D, Kleinman H: Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-246.
85. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
86. Brooks PC, Stromblad S, Sanders LC, Von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with αvβ3. Cell 1996;85:683-693.
87. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
88. Schnaper WH, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, Baricos WH, Kleinman HK: Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995;165:107-118.
89. Pepper MS, Belin D, Montesano R, Orci L, Vassalli J-D: Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990;111:743-755.
90. Bajou K, Noël A, Gerard RD, Brunner N, Holst-Hansen C, Skobe M, Fusenig N, Carmeliet P, Collen D, Foidard JM: Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-928.
91. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
92. Dong Z, Kumar R, Yang X, Fidler IJ: Macrophae-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810.
93. Patterson BC, QingXiang AS: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272: 28823-28825.
94. Blasi F: uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997;18:415-417.
95. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-1571.
96. Edwards DR, Murphy G: Proteases-invasion and more. Nature 1998;394:527-528.
97. Werb Z: ECM and cell surface proteolysis regulating cellular ecology. Cell 1997;91:439-442.
98. Basbaum CB, Werb Z: Focalized proteolysis: Spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 1996;8:731-738.
99. Preece G, Murphy G, Ager A: Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem 1996;271: 11634-11640.
100. Arribas J, Lavanya C, Vollmer P, Kishimoto TK, Rose-John S, Massagué J: Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996;271: 11376-11382.
101. Bracke ME, Van Roy FM, Mareel MM: The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 1996;213:123-161.
102. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861-1872.
103. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997;275:1784-1787.